Cipla Receives US FDA Approval For Generic Imitrex
Cipla Limited has received final approval for its Abbreviated New Drug Application (ANDA) for sumatriptan nasal spray, 20 mg from the United States Food and Drug Administration (FDA).Cipla's sumatriptan nasal spray USP, 20 mg is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline's Imitrex nasal spray.Imitrex nasal spray is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults.According to IQVIA (IMS Health), Imitrex nasal spray 20mg and its generic equivalents had US sales of approximately $53.3 million for the 12-month period ending December 2020.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!